Business Context and Reporting Period
CareDx, Inc. (CDNA) filed a Form 8-K on April 15, 2026, reporting the entry into a Material Definitive Agreement. The filing also references preliminary unaudited financial results for the quarter ended March 31, 2026, though specific figures are contained in an attached press release not included in the source text.
Key Financial Metrics and Transaction Details
- Transaction Value: CareDx agreed to sell its wholly-owned Swedish subsidiary (CareDx AB) and its kitted laboratory products business (including related software) to Eurobio Scientific S.A. for $170 million in cash.
- Adjustments: The purchase price is subject to customary adjustments for working capital, cash, and indebtedness.
- Financial Results: The filing references preliminary results for the quarter ended March 31, 2026, but does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity within the text provided.
Material Changes and Strategic Shifts
The primary material change is the divestiture of the kitted laboratory products business. Post-transaction, CareDx will retain the exclusive right to distribute Eurobio's NGS- and PCR-based post-transplant assays (including AlloSeq cfDNA, AlloSeq HCT, NGStrack, and KMRtrack) in the US, Canada, and Mexico. Conversely, Eurobio retains the exclusive right to sell CareDx's current chimerism assay to existing customers in North America for three years post-closing.
Guidance, Risks, and Contingencies
- Closing Conditions: The transaction is subject to customary conditions, including regulatory approvals, accuracy of representations, and the absence of a material adverse effect on the business.
- Termination Rights: Either party may terminate if the transaction is not consummated by October 15, 2026, or if there is an uncured material breach or material adverse effect.
- Forward-Looking Risks: Risks include failure to obtain regulatory approvals, delays in closing, or termination of the agreement. The company disclaims any obligation to update forward-looking statements.
- Transition Services: A transition services agreement will be entered into at closing.
Investor Verification Checklist
- Verify the specific preliminary financial results for the quarter ended March 31, 2026, by reviewing the attached Press Release (Exhibit 99.1).
- Confirm the status of required regulatory approvals for the sale of CareDx AB and the kitted laboratory business.
- Review the full text of the Purchase Agreement (Exhibit 2.1) for detailed representations, warranties, and specific adjustment mechanics.
- Assess the impact of the divestiture on CareDx's future revenue streams, specifically the shift from manufacturing kitted products to distributing Eurobio's assays.